Lipella Historical Balance Sheet

LIPO Stock

2.76 0.06 2.22%

Trend analysis of Lipella Pharmaceuticals Common balance sheet accounts such as Total Current Liabilities of 501.1 K provides information on Lipella Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Lipella Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Lipella Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Lipella Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lipella Pharmaceuticals is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About Lipella Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lipella Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Lipella Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lipella Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lipella currently owns. An asset can also be divided into two categories, current and non-current.

Lipella Pharmaceuticals Balance Sheet Chart

At this time, Lipella Pharmaceuticals' Short Term Debt is very stable compared to the past year. As of the 17th of December 2024, Common Stock is likely to grow to 712.80, while Total Assets are likely to drop about 2.8 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Other Liab

Total Assets

Total assets refers to the total amount of Lipella Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lipella Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lipella Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lipella Pharmaceuticals Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Lipella Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lipella Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	283.0K	429.5K	136.6K	129.8K
Total Assets	2.0M	6.0M	3.6M	2.8M

Short Long Term Debt Total Total Assets

Lipella Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt
Total Assets		0.68	0.71	0.94	1.0	0.86	0.89	-0.98	-0.78	0.91	1.0	1.0	0.01	0.49	0.09	0.92	0.89	0.93	1.0	0.88	0.4	-0.93	0.88	-0.93	0.73	-0.42
Short Long Term Debt Total	0.68		0.37	0.69	0.64	0.57	0.39	-0.56	-0.21	0.57	0.64	0.65	0.33	-0.02	0.71	0.69	0.36	0.82	0.66	0.79	0.4	-0.43	0.51	-0.43	0.16	0.09
Other Current Liab	0.71	0.37		0.82	0.7	0.31	0.56	-0.71	-0.42	0.91	0.73	0.7	0.03	0.19	-0.38	0.83	0.6	0.68	0.73	0.82	-0.32	-0.54	0.35	-0.54	0.37	-0.16
Total Current Liabilities	0.94	0.69	0.82		0.92	0.65	0.75	-0.91	-0.58	0.98	0.93	0.93	0.26	0.33	0.03	1.0	0.72	0.97	0.95	0.96	0.26	-0.79	0.71	-0.79	0.52	-0.25
Total Stockholder Equity	1.0	0.64	0.7	0.92		0.88	0.91	-0.99	-0.81	0.89	1.0	1.0	-0.04	0.51	0.05	0.9	0.92	0.9	1.0	0.85	0.4	-0.94	0.9	-0.94	0.76	-0.45
Other Liab	0.86	0.57	0.31	0.65	0.88		0.88	-0.85	-0.85	0.58	0.86	0.87	-0.26	0.58	0.26	0.6	0.9	0.7	0.85	0.57	0.63	-0.91	0.96	-0.91	0.83	-0.54
Net Tangible Assets	0.89	0.39	0.56	0.75	0.91	0.88		-0.95	-0.97	0.73	0.9	0.9	-0.35	0.82	-0.1	0.71	0.92	0.74	0.89	0.68	0.42	-0.99	0.85	-0.99	0.96	-0.78
Net Debt	-0.98	-0.56	-0.71	-0.91	-0.99	-0.85	-0.95		0.86	-0.9	-0.99	-0.99	0.1	-0.62	0.05	-0.89	-0.92	-0.89	-0.98	-0.84	-0.37	0.97	-0.87	0.97	-0.82	0.56
Retained Earnings	-0.78	-0.21	-0.42	-0.58	-0.81	-0.85	-0.97	0.86		-0.58	-0.79	-0.79	0.51	-0.88	0.18	-0.54	-0.91	-0.56	-0.77	-0.49	-0.41	0.95	-0.81	0.95	-1.0	0.86
Accounts Payable	0.91	0.57	0.91	0.98	0.89	0.58	0.73	-0.9	-0.58		0.91	0.9	0.19	0.31	-0.16	0.98	0.75	0.9	0.92	0.93	0.09	-0.76	0.66	-0.76	0.52	-0.25
Cash	1.0	0.64	0.73	0.93	1.0	0.86	0.9	-0.99	-0.79	0.91		1.0	-0.03	0.49	0.03	0.91	0.91	0.91	1.0	0.87	0.36	-0.93	0.88	-0.93	0.75	-0.44
Cash And Short Term Investments	1.0	0.65	0.7	0.93	1.0	0.87	0.9	-0.99	-0.79	0.9	1.0		-0.01	0.5	0.06	0.91	0.91	0.91	1.0	0.86	0.41	-0.94	0.9	-0.94	0.75	-0.44
Net Receivables	0.01	0.33	0.03	0.26	-0.04	-0.26	-0.35	0.1	0.51	0.19	-0.03	-0.01		-0.55	0.29	0.3	-0.34	0.28	0.02	0.21	0.21	0.23	-0.06	0.23	-0.55	0.62
Common Stock Shares Outstanding	0.49	-0.02	0.19	0.33	0.51	0.58	0.82	-0.62	-0.88	0.31	0.49	0.5	-0.55		-0.23	0.29	0.6	0.35	0.48	0.28	0.39	-0.75	0.51	-0.75	0.91	-0.99
Non Current Liabilities Total	0.09	0.71	-0.38	0.03	0.05	0.26	-0.1	0.05	0.18	-0.16	0.03	0.06	0.29	-0.23		0.02	-0.15	0.25	0.05	0.14	0.54	0.06	0.15	0.06	-0.2	0.27
Other Current Assets	0.92	0.69	0.83	1.0	0.9	0.6	0.71	-0.89	-0.54	0.98	0.91	0.91	0.3	0.29	0.02		0.69	0.96	0.93	0.96	0.24	-0.75	0.68	-0.75	0.48	-0.21
Other Stockholder Equity	0.89	0.36	0.6	0.72	0.92	0.9	0.92	-0.92	-0.91	0.75	0.91	0.91	-0.34	0.6	-0.15	0.69		0.67	0.9	0.62	0.31	-0.94	0.9	-0.94	0.87	-0.57
Total Liab	0.93	0.82	0.68	0.97	0.9	0.7	0.74	-0.89	-0.56	0.9	0.91	0.91	0.28	0.35	0.25	0.96	0.67		0.93	0.96	0.42	-0.78	0.73	-0.78	0.51	-0.27
Total Current Assets	1.0	0.66	0.73	0.95	1.0	0.85	0.89	-0.98	-0.77	0.92	1.0	1.0	0.02	0.48	0.05	0.93	0.9	0.93		0.88	0.38	-0.92	0.88	-0.92	0.72	-0.42
Short Term Debt	0.88	0.79	0.82	0.96	0.85	0.57	0.68	-0.84	-0.49	0.93	0.87	0.86	0.21	0.28	0.14	0.96	0.62	0.96	0.88		0.15	-0.69	0.57	-0.69	0.44	-0.22
Common Stock	0.4	0.4	-0.32	0.26	0.4	0.63	0.42	-0.37	-0.41	0.09	0.36	0.41	0.21	0.39	0.54	0.24	0.31	0.42	0.38	0.15		-0.5	0.67	-0.5	0.41	-0.32
Property Plant And Equipment Net	-0.93	-0.43	-0.54	-0.79	-0.94	-0.91	-0.99	0.97	0.95	-0.76	-0.93	-0.94	0.23	-0.75	0.06	-0.75	-0.94	-0.78	-0.92	-0.69	-0.5		-0.91	1.0	-0.92	0.7
Current Deferred Revenue	0.88	0.51	0.35	0.71	0.9	0.96	0.85	-0.87	-0.81	0.66	0.88	0.9	-0.06	0.51	0.15	0.68	0.9	0.73	0.88	0.57	0.67	-0.91		-0.91	0.77	-0.45
Non Current Assets Total	-0.93	-0.43	-0.54	-0.79	-0.94	-0.91	-0.99	0.97	0.95	-0.76	-0.93	-0.94	0.23	-0.75	0.06	-0.75	-0.94	-0.78	-0.92	-0.69	-0.5	1.0	-0.91		-0.92	0.7
Non Currrent Assets Other	0.73	0.16	0.37	0.52	0.76	0.83	0.96	-0.82	-1.0	0.52	0.75	0.75	-0.55	0.91	-0.2	0.48	0.87	0.51	0.72	0.44	0.41	-0.92	0.77	-0.92		-0.89
Long Term Debt	-0.42	0.09	-0.16	-0.25	-0.45	-0.54	-0.78	0.56	0.86	-0.25	-0.44	-0.44	0.62	-0.99	0.27	-0.21	-0.57	-0.27	-0.42	-0.22	-0.32	0.7	-0.45	0.7	-0.89

Click cells to compare fundamentals

Lipella Pharmaceuticals Account Relationship Matchups

Pair Trading with Lipella Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipella Stock

0.66	BMY	Bristol Myers Squibb	Pair Corr
0.58	GILD	Gilead Sciences	Pair Corr
0.43	DYAI	Dyadic International	Pair Corr
0.43	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.

The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock:

How To Invest In Lipella

Details

Is Lipella Stock a good investment?

Details

What is Lipella Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.88)

Revenue Per Share

0.592

Quarterly Revenue Growth

0.279

Return On Assets

(0.94)

Return On Equity

(1.72)

The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipella Historical Balance Sheet

About Lipella Balance Sheet Analysis

Lipella Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Lipella Pharmaceuticals balance sheet Correlations

Lipella Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Lipella Pharmaceuticals

Moving against Lipella Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity

Non Currrent Assets Other	- 1.0	Retained Earnings
Long Term Debt	- 0.99	Common Stock Shares Outstanding
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Non Current Assets Total	- 0.99	Net Tangible Assets
Property Plant And Equipment Net	- 0.99	Net Tangible Assets